||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Quantum Phar. Share Discussion Threads
Showing 1276 to 1299 of 1300 messages
|Maybe the curse of Zeus has been lifted today.|
|A reliable firm Schroders I always think........with fairly sound judgement.
|Ah! Schroders plc & Schroder Investment Management Limited that explains a bit of interest last week.
|I see the directors have their noses in the trough..............despite the 140p price target it seems a nice reward for the recent failures
|Forward PE anyone?|
|lets hope so A2584728...
ITS certainly better than it was!|
|Ready for the next rise I think.|
|OK. But post 372 still applies.|
|Zeus are one of the better NOMAD / Brokers in town in my opinion.|
|Their Nomad. as always avoid any new issue under which existing shareholder is exiting for at least 2 years from listing date|
|What's the curse of Zeus and the relevance to QP? Or are you one of those nutters that we shouldn't encourage?|
|Curse of Zeus?|
|Good! Stability in securing a permanent chief executive|
|New boss for North East firm as it aims to raise £15million from markets
14:24, 20 OCT 2016 UPDATED 14:24, 20 OCT 2016
BY GRAEME WHITFIELD
Chris Rigg has been acting CEO of firm Quantum since August but has now been appointed permanent chief executive
Pharmaceutical firm Quantum has appointed a new chief executive and chairman and raised £15m from the markets as it seeks to recover from recent troubles.
Chris Rigg, who has previously worked for Deloitte, Barclays and recruitment firm NRG in the North East, has been acting CEO since August and has now been confirmed in the top job.
Quantum Pharma Plc issued a profit warning earlier this month and saw its share price plunge, but Mr Rigg has been backed by major shareholders in his strategy to simplify the hotly-tipped group and concentrate on its core specials business and niche pharmaceuticals pipeline.
The firm has also appointed a new chairman, Ian Johnson, and two new non-executive directors - Christopher Mills and Dr John Brown – in a wideranging set of changes at the group’s board level.
Quantum Pharma laboratories
This morning the company had announced plans for an “accelerated bookbuild” that aimed to raise £15m to help reduce its debt. Just over an hour later, the company announced that the process had been successful.
Shares in Quantum rose more than 25% after the announcements.
Mr Rigg, who will remain as finance chief as well as CEO until a replacement is found, said: “I am delighted to be appointed as Quantum’s CEO and would like to thank the board and our major shareholders for their support.
“Whilst the group has faced some challenges in the recent past, the focused and simplified strategy now in place has the potential to drive shareholder value and I look forward to working with Ian, Christopher, John and Quantum’s senior management team to deliver this.”
Quantum warned earlier this month that its full-year results would be below forecasts, even though its six months to July 31 were strong, with revenues rising from £34.3m to £42.8m.
The firm is also proposing to close a manufacturing operation in North Wales, a move affecting 66 employees.
Mr Rigg replaces Andrew Scaife, who resigned in July. It has now been announced that chairman John Clarke and non-executive director Sheila Kelly have resigned from the company’s board.|
|60p short term should be achievable.|
|Quantum Pharma conditionally raises £15m in accelerated bookbuild
Thu, 20th Oct 2016 11:35
(ShareCast News) - Quantum Pharma confirms its accelerated bookbuild to raise up to £15m has closed successfully, subject to the passing of certain resolutions by shareholders at the company's annual meeting.
The company, which noted that it continued to trade in line, believed net proceeds would reduce its net debt to a more appropriate level for the group's type and size.
"Proceeds ... will initially be used to reduce the level of utilisation of the group's revolving credit facility, which will create headroom in the group's debt facilities, allowing increased operational and commercial flexibility," the company said.
"The reduced level of net debt will allow the group to be able to invest in its business without decisions being constrained by the need to actively manage cash and debt levels."
Shareholders would vote on the bookbuild at the company's annual meeting, which was to be convened shortly.|
|web site has been updated with new director details.|
|Hi Hazl. I know I'm sounding negative but I bought shares at £1.29 then seen them plummet due to promises not kept and sheer NuPharm incompetence.Reducing the debt would be great but can they be trusted to do so?|
|I think its a shame to tread on any rise.
That's got to be good news surely?
This is a phrase that I don't use often,but I would have thought this could well be a takeover target.
It's a little niche business serving the individual that doesn't fit into the usual category.
Thank goodness for some firms like this from a patien'ts point of view.
If you are unfortunate enough to have some illness that is not common then the big firms don't want to know.
It's not as easy to make a profit for them.
Await the details.imo|
|Assuming they do use the extra cash to reduce debt and not go off on another badly thought out NuPharm jolly. "Like a child in a sweetie shop with too much pocket money"Do they have a new boss to ensure the money is spent wisely?|
|Glad I got back in this, oversold imo|
|That was fast, must be something investors like. Mind they have profit already.|